Director, Ragon Institute of MGH, MIT and Harvard
Professor of Medicine, Harvard University
Investigator, Howard Hughes Medical Institute
400 Technology Square, Room 870
Cambridge, MA 02139
Dr. Bruce Walker is the Director of the Ragon Institute of MGH, MIT and Harvard, a Professor of Medicine at Harvard Medical School, and a Howard Hughes Medical Institute Investigator. In addition to his clinical duties as a board certified Infectious Disease specialist, his research focuses on cellular immune responses in chronic viral infections, with a particular focus on HIV. He leads an international translational clinical and basic science research effort to understand how some rare people who are infected with HIV, but have never been treated, can fight the virus with their immune system. Dr. Walker is also an Adjunct Professor at the Nelson Mandela School of Medicine in Durban, South Africa. There he collaborates with the Doris Duke Medical Research Institute at the University of KwaZulu-Natal and serves as a Principal Investigator in the HIV Pathogenesis Program, an initiative to study the evolution of the HIV and the immune responses effective in controlling this virus, as well as to contribute to training the next generation of African scientists. He is a member of the Steering Committee for the KwaZulu-Natal Research Institute for TB and HIV (K-RITH), a 10-year initiative funded by HHMI to build a state of the art TB-HIV research facility at the heart of these dual epidemics in South Africa. Dr. Walker is a member of the American Academy of Arts and Sciences, American Society for Clinical Investigation (ASCI), the American Association of Physicians (AAP), and the Institute of Medicine (IOM) of the National Academy of Sciences.
Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature. 2010 Mar 11;464(7286):224-31.PMID: 20220841.
Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, Walker BD, Ho DD, Wilson PC, Seaman MS, Eisen HN, Chakraborty AK, Hope TJ, Ravetch JV, Wardemann H, Nussenzweig MC. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010 Sep 30;467(7315):591-5. PubMed PMID: 20882016.
Pereyra F, Jia X, McLaren PJ, Telenti A, De Bakker P, Walker BD. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation; The International HIV Controller Study. Science 2010 Dec 10; 330(6010):1551-1557. [Epub ahead of print] 2010 Nov 4 PubMed PMID: 21051598
Dahirel V, Shekhar K, Pereyra F, Miura T, Artyomov M, Talsania S, Allen TM, Altfeld M, Carrington M, Irvine DJ, Walker BD, Chakraborty AK. Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc Natl Acad Sci U S A. 2011 Jun 20. [Epub ahead of print] PubMed PMID: 21690407.
Chen H, Ndhlovu, Z, Liu D, Porter LC, Fang JW, Darko S, Brockman MA, Miura T, Brumme ZL, Schneidewind A, Trocha A, Cesa KT, Sela J, Cung TD, Toth I, Pereyra F, Yu XG, Douek DC, Kaufmann DE, Allen TM, Walker BD.TCR clonotypes modulate the protective effect of HLA class I alleles in HIV-1 infection. Nature Immunology. 2012. In press.
Last Update: 1/6/2014